永久起搏器患者亚临床房颤负荷与不良临床结局
本研究纳入496例无房颤病史的永久起搏器患者,按6个月亚临床房颤(SCAF)负荷分为无、低负荷(<24小时)和高负荷(≥24小时)三组。中位随访5.2年发现,高负荷SCAF与复合不良结局风险独立相关(OR=20.1,95%CI 7.60-52.7,P<0.001),主要由临床房颤进展和缺血性卒中驱动。
要点
- 高负荷SCAF(6个月≥24小时)与复合不良结局风险显著增加独立相关。
- 高负荷SCAF均先于缺血性卒中事件出现,提示其预警价值。
- 高负荷SCAF患者临床房颤进展风险极高(OR=36.2)。
核心结论
- 在无房颤病史的永久起搏器患者中,高负荷SCAF与复合不良结局风险增加密切相关,尤其是临床房颤进展和缺血性卒中。
研究设计与样本
- 回顾性队列研究,连续纳入496例无房颤病史的永久起搏器患者,中位随访5.2年,按6个月SCAF负荷分组。
主要发现
- 高负荷SCAF组复合不良结局风险最高(P<0.001),主要由临床房颤进展(P<0.001)和缺血性卒中(P<0.001)驱动。
- 高负荷SCAF与复合不良结局独立相关(OR=20.1,95%CI 7.60-52.7,P<0.001)。
- 高负荷SCAF与临床房颤进展独立相关(OR=36.2,95%CI 15.9-87.8,P<0.001)。
- 高负荷SCAF均先于缺血性卒中事件出现。
关键数值与推荐
- SCAF负荷分组:无SCAF(任何设备分析均无SCAF发作,n=152);低负荷SCAF(至少一次设备分析6个月SCAF<24小时,n=287);高负荷SCAF(至少一次设备分析6个月SCAF≥24小时,n=57)。
临床怎么用
- 对永久起搏器患者应关注设备记录的SCAF负荷,高负荷SCAF(6个月≥24小时)提示临床房颤和卒中风险显著增加。
- 高负荷SCAF且高卒中风险患者的抗凝治疗策略尚需前瞻性研究确定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Unlike clinical atrial fibrillation (AF), the significance of subclinical AF (SCAF) burden in patients with permanent pacemakers has not been fully evaluated. METHODS: We investigated whether the SCAF burden was associated with increased risks of composite adverse outcomes, including progression to clinical AF, ischemic stroke, myocardial infarction, heart failure-related hospitalization, or cardiac death, in patients without previous AF. To quantify the 6-month SCAF burden, the total cumulative time spent in SCAF during every 6-month follow-up was summed. RESULTS: During the median 5.2-year follow-up, 496 consecutive permanent pacemaker patients were classified into the no SCAF (no SCAF episode in any device analysis; n=152), low-burden SCAF (6-month SCAF <24 hours in at least one device analysis; n=287), or high-burden SCAF (6-month SCAF ≥24 hours in at least 1 device analysis; n=57) groups. The risk of composite adverse outcomes was greatest in the high-burden SCAF group (P<0.001) and was primarily driven by progression to clinical AF (P<0.001) and ischemic stroke (P<0.001). The presence of high-burden SCAF, which always preceded ischemic stroke events, was independently associated with composite adverse outcomes (odds ratio=20.1 [95% CI, 7.60-52.7], P<0.001) and progression to clinical AF (odds ratio, 36.2 [95% CI, 15.9-87.8], P<0.001). CONCLUSIONS: In permanent pacemaker patients without preexisting AF, the presence of high-burden SCAF was closely associated with increased risks of composite adverse outcomes, particularly progression to clinical AF and ischemic stroke. Therefore, prospective studies deserve to be performed on the optimal anticoagulation therapy for permanent pacemaker patients with both high-burden SCAF and high stroke risk.
引用
- Park YJ, Kim JS, Park KM, et al. Subclinical Atrial Fibrillation Burden and Adverse Clinical Outcomes in Patients With Permanent Pacemakers. Stroke. 2021. PMID: 33588601. doi:10.1161/STROKEAHA.120.031822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。